Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
ledipasvir/sofosbuvir (Harvoni®)
Reference No. 1887
Publication date:
12/08/2015
Appraisal information
ledipasvir/sofosbuvir (Harvoni®) 90 mg/400 mg film-coated tablet
Company:
Gilead Sciences Ltd
BNF category:
Infections
NMG meeting date:
18/03/2015
AWMSG meeting date:
22/04/2015
Submission Type:
Full Submission
Status:
Superseded
Advice No:
0915
Ratification by Welsh Government:
12/08/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA363) NICE GUIDANCE ISSUED NOVEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Ledipasvir/sofosbuvir (Harvoni®) is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C in adults with hepatitis C virus genotype 1 and 4 without cirrhosis or with compensated cirrhosis for up to 12 weeks. Ledipasvir/sofosbuvir (Harvoni®) is not recommended for use within NHS Wales outside of this subpopulation/these circumstances. Key factor(s) influencing the recommendation: The cost effectiveness data presented in the submission were insufficient for AWMSG to recommend use beyond 12 weeks. No economic data were provided for genotype 1 or 4 patients with decompensated cirrhosis or who are pre-/post liver transplant. Similarly, no economic data were provided for genotype 3 patients with cirrhosis and/or prior treatment failure.
Final Appraisal Recommendation (FAR)
Download
ledipasvir sofosbuvir (Harvoni) 1887 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
ledipasvir sofosbuvir (Harvoni) 1887 ASAR
Clinical Expert (CE) Summary
Download
ledipasvir sofosbuvir (Harvoni) 1887 CE summary